Total Payments
$1.1M
2024 Payments
$168,419
Companies
44
Transactions
750
Medicare Patients
1,683
Medicare Billing
$197,853
Payment Breakdown by Category
Consulting$549,673 (51.7%)
Research$262,949 (24.7%)
Other$206,861 (19.5%)
Travel$24,299 (2.3%)
Food & Beverage$18,890 (1.8%)
Education$265.54 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $549,673 | 174 | 51.7% |
| Unspecified | $262,949 | 73 | 24.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $165,221 | 55 | 15.5% |
| Honoraria | $37,790 | 13 | 3.6% |
| Travel and Lodging | $24,299 | 58 | 2.3% |
| Food and Beverage | $18,890 | 369 | 1.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,850 | 1 | 0.4% |
| Education | $265.54 | 7 | 0.0% |
Payments by Type
General
$799,988
677 transactions
Research
$262,949
73 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| LEO Pharma Inc. | $250,163 | 53 | $0 (2024) |
| PFIZER INC. | $194,740 | 159 | $0 (2024) |
| Eli Lilly and Company | $90,925 | 46 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $57,270 | 33 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $51,882 | 52 | $0 (2024) |
| GENZYME CORPORATION | $50,305 | 18 | $0 (2024) |
| ABBVIE INC. | $37,387 | 22 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $33,907 | 50 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $33,866 | 32 | $0 (2024) |
| UCB, Inc. | $28,066 | 28 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $168,419 | 113 | Eli Lilly and Company ($38,564) |
| 2023 | $128,710 | 109 | Eli Lilly and Company ($26,570) |
| 2022 | $149,809 | 81 | GENZYME CORPORATION ($22,526) |
| 2021 | $159,739 | 80 | PFIZER INC. ($62,926) |
| 2020 | $121,824 | 45 | PFIZER INC. ($38,655) |
| 2019 | $142,959 | 146 | LEO Pharma Inc. ($71,789) |
| 2018 | $163,701 | 109 | LEO Pharma Inc. ($104,740) |
| 2017 | $27,775 | 67 | Allergan Inc. ($10,841) |
All Payment Transactions
750 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Xolair (Biological) | — | In-kind items and services | $3,727.50 | Research |
| Study: Efficacy Outcomes in Phase III Trials for Omalizumab and Dupilumab for Patients With Chronic Spontaneous Urticaria • Category: Immunology | ||||||
| 12/20/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: Dermatology | ||||||
| 12/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,775.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: DERMATOLOGY | ||||||
| 12/14/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Dermatology | ||||||
| 12/14/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $134.33 | General |
| Category: Dermatology | ||||||
| 12/13/2024 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,312.50 | General |
| 12/13/2024 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $49.33 | General |
| Category: Inflammation & Immunology | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,775.00 | General |
| 12/09/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $854.00 | General |
| Category: Immunology | ||||||
| 11/26/2024 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,175.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $52.18 | General |
| Category: DERMATOLOGY | ||||||
| 11/19/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $42.80 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $9.50 | General |
| Category: Inflammation & Immunology | ||||||
| 10/28/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 10/25/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: Dermatology | ||||||
| 10/24/2024 | Eli Lilly and Company | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $115.21 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $59.73 | General |
| Category: Dermatology | ||||||
| 10/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $51.30 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $962.00 | General |
| 10/08/2024 | Eli Lilly and Company | TALTZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Immunology | ||||||
| 09/30/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Consulting Fee | Cash or cash equivalent | $14,040.00 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PENDING AN OPEN-LABEL, SINGLE-CENTER STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF ENSTILAR CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE FOAM IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS IN PATIENTS WITH SKIN OF COLOR FITZPATRICK SKIN PHOTOTYPES IV-VI. | LEO Pharma Inc. | $165,202 | 7 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $35,050 | 30 |
| PENDING: AN OPEN-LABEL, SINGLE-CENTER STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF ENSTILAR? (CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE) FOAM IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS IN PATIENTS WITH SKIN OF COLOR (FITZPATRICK SKIN PHOTOTYPES IV-VI). | LEO Pharma Inc. | $30,000 | 1 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $12,209 | 17 |
| Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients with Chronic Spontaneous Urticaria | F. Hoffmann-La Roche AG | $5,046 | 2 |
| Efficacy Outcomes in Phase III Trials for Omalizumab and Dupilumab for Patients With Chronic Spontaneous Urticaria | F. Hoffmann-La Roche AG | $3,728 | 1 |
| Dupixent Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $3,147 | 3 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,663 | 2 |
| SOLO 1; SOLO 2 | SANOFI-AVENTIS U.S. LLC | $1,574 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,458 | 2 |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis (CC-10004-PSOR-008) | Celgene Corporation | $1,144 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $781.36 | 3 |
| Health economic and outcomes research related to Dupixent | Regeneron Pharmaceuticals, Inc. | $687.72 | 2 |
| AN EXPLORATORY RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY TO EXPLORE THE MODULATION OF INFLAMMATION IN THE SKIN CUTANEOUS ADIPOSE TISSUE AND BLOOD ENDOTHELIAL CELL INTERFACE BY COSENTYX SECUKINUMAB VERSUS PLACEBO IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS ADIPSO | Novartis Pharmaceuticals Corporation | $259.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 428 | 660 | $201,876 | $55,711 |
| 2022 | 11 | 395 | 675 | $195,136 | $54,872 |
| 2021 | 12 | 470 | 659 | $190,016 | $53,717 |
| 2020 | 10 | 390 | 477 | $160,933 | $33,553 |
Total Patients
1,683
Total Services
2,471
Medicare Billing
$197,853
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 166 | 311 | $105,740 | $33,723 | 31.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 42 | 42 | $22,050 | $5,206 | 23.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 40 | 47 | $16,685 | $4,162 | 24.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 26 | 32 | $13,760 | $3,316 | 24.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 36 | 42 | $9,660 | $3,105 | 32.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 34 | 45 | $13,500 | $2,141 | 15.9% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 16 | 28 | $8,960 | $1,366 | 15.3% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 11 | 11 | $4,895 | $1,328 | 27.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 16 | 21 | $3,990 | $1,009 | 25.3% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 25 | 53 | $2,120 | $334.33 | 15.8% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 16 | 28 | $516.00 | $19.87 | 3.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 155 | 287 | $97,580 | $31,551 | 32.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 65 | 65 | $34,125 | $8,872 | 26.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 31 | 33 | $11,715 | $3,082 | 26.3% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 17 | 20 | $8,900 | $2,517 | 28.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 16 | 18 | $7,740 | $2,005 | 25.9% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2022 | 16 | 39 | $12,480 | $1,922 | 15.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 30 | 36 | $10,800 | $1,876 | 17.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 24 | $5,520 | $1,857 | 33.6% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 11 | 14 | $2,660 | $702.03 | 26.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 18 | 67 | $2,680 | $430.03 | 16.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 16 | 72 | $936.00 | $60.63 | 6.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 140 | 205 | $72,040 | $23,022 | 32.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 80 | 119 | $29,525 | $8,772 | 29.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 56 | 56 | $19,510 | $5,657 | 29.0% |
About Dr. Andrew Alexis, MD
Dr. Andrew Alexis, MD is a Dermatology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1285625160.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Alexis, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $168,419 received in 2024. These payments were reported across 750 transactions from 44 companies. The most common payment nature is "Consulting Fee" ($549,673).
As a Medicare-enrolled provider, Alexis has provided services to 1,683 Medicare beneficiaries, totaling 2,471 services with total Medicare billing of $197,853. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Procedural Dermatology, Dermatology
- Location New York, NY
- Active Since 10/31/2005
- Last Updated 04/14/2022
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1285625160
Products in Payments
- ENSTILAR (Drug) $204,326
- DUPIXENT (Biological) $93,880
- EUCRISA (Drug) $72,345
- CIBINQO (Drug) $40,204
- COSENTYX (Biological) $31,060
- TREMFYA (Drug) $23,465
- DUPIXENT DUPILUMAB INJECTION (Biological) $17,549
- VTAMA (Drug) $14,779
- Cimzia (Drug) $12,690
- TAPINAROF (Drug) $11,700
- TALTZ (Drug) $11,198
- AKLIEF (Drug) $10,857
- OPZELURA (Drug) $9,920
- Xolair (Biological) $9,193
- ARAZLO (Drug) $8,520
- ADBRY (Biological) $7,887
- Bimzelx (Biological) $7,338
- ALTRENO (Drug) $5,881
- Seysara (Drug) $5,200
- SKYRIZI (Biological) $4,589
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in New York
David Cohen, M.d, M.D
Dermatology — Payments: $3.1M
Dermatology $3.1M
Dr. Amy Wechsler, M.d, M.D
Dermatology — Payments: $2.8M
Dermatology $2.8M
Dr. Alexandra Golant, M.d, M.D
Dermatology — Payments: $2.7M
Dermatology $2.7M
Emma Guttman, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Dr. Joshua Zeichner, Md, MD
Dermatology — Payments: $2.1M
Dermatology $2.1M
Dr. Mark Lebwohl
Dermatology — Payments: $2.0M
Dermatology $2.0M